BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li Q, Wang Z, Zheng Q, Liu S. Potential clinical drugs as covalent inhibitors of the priming proteases of the spike protein of SARS-CoV-2. Comput Struct Biotechnol J 2020;18:2200-8. [PMID: 32868983 DOI: 10.1016/j.csbj.2020.08.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Li QZ, Zuo ZW, Liu Y. Recent status of sesaminol and its glucosides: Synthesis, metabolism, and biological activities. Crit Rev Food Sci Nutr 2022;:1-14. [PMID: 35821660 DOI: 10.1080/10408398.2022.2098248] [Reference Citation Analysis]
2 Manhas RS, Tiwari H, Noor M, Ahmed A, Vishwakarma J, Tripathi RBM, Ramachandran R, Madishetti S, Mukherjee D, Chaubey A, Nargotra A. Setomimycin as a potential molecule for COVID‑19 target: in silico approach and in vitro validation. Mol Divers 2022. [PMID: 35622309 DOI: 10.1007/s11030-022-10441-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Raj V, Lee JH, Shim JJ, Lee J. Antiviral activities of 4H-chromen-4-one scaffold-containing flavonoids against SARS-CoV-2 using computational and in vitro approaches. J Mol Liq 2022;:118775. [PMID: 35194277 DOI: 10.1016/j.molliq.2022.118775] [Reference Citation Analysis]
4 Choudhary V, Gupta A, Sharma R, Parmar HS. Therapeutically effective covalent spike protein inhibitors in treatment of SARS-CoV-2. J Proteins Proteom 2021;:1-14. [PMID: 34539131 DOI: 10.1007/s42485-021-00074-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Hatmal MM, Abuyaman O, Taha M. Docking-generated multiple ligand poses for bootstrapping bioactivity classifying Machine Learning: Repurposing covalent inhibitors for COVID-19-related TMPRSS2 as case study. Comput Struct Biotechnol J 2021;19:4790-824. [PMID: 34426763 DOI: 10.1016/j.csbj.2021.08.023] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
6 Watashi K. Identifying and repurposing antiviral drugs against severe acute respiratory syndrome coronavirus 2 with in silico and in vitro approaches. Biochem Biophys Res Commun 2021;538:137-44. [PMID: 33272566 DOI: 10.1016/j.bbrc.2020.10.094] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]